Shares of Hikma Pharmaceuticals PLC HIK inched down 0.35% to £19.82 Friday, on what proved to be an all-around favorable ...

The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...

Shares of Hikma Pharmaceuticals PLC HIK inched up 0.05% to £19.89 Tuesday, on what proved to be an all-around great trading ...

(HealthDay News) — The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

Most readers would already be aware that Hikma Pharmaceuticals' (LON:HIK) stock increased significantly by 5.3% over the past month. As most would know, fundamentals are what usually guide market ...

FDA approves Hikma Pharmaceuticals' generic version of Victoza, a once-daily GLP-1 injection for Type 2 diabetes. Other drugmakers also entering the market.

Shares of Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 1,921.22 ($24.37) and ...

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...